A phase II study of cabozantinib and temozolomide in advanced progressive gastroenteropancreatic or lung neuroendocrine tumors (NETs)

被引：0
|
作者：
Clemente, O. [1 ]
Cives, M. [2 ]
Guerrera, L. P. [1 ]
Tornesello, M. L. [3 ]
Bracigliano, A. [4 ]
Lauricella, E. [5 ]
Ragno, A. [2 ]
Scarpati, G. Della Vittoria [1 ]
Starita, N. [3 ]
Picozzi, F. [1 ]
Barretta, M. L. [6 ]
Badalamenti, G. [2 ,7 ]
Cannella, L. [1 ]
Lastoria, S. [4 ]
Di Mauro, A. [8 ]
Porta, C. G. [2 ]
Tafuto, S. [1 ]
机构：
[1] Ist Nazl Tumori IRCCS Fdn G Pascale, Rare Tumors & Sarcomas Dept, Naples, Italy
[2] Azienda Osped Univ Consorziale Policlin Bari, Med Oncol Unit, Bari, Italy
[3] Ist Nazl Tumori IRCCS Fdn G Pascale, Unit Mol Biol & Viral Oncogenesis, Naples, Italy
[4] Ist Nazl Tumori IRCCS Fdn G Pascale, Nucl Med Unit, Naples, Italy
[5] Univ Bari Aldo Moro, Interdisciplinary Dept Med, Bari, Italy
[6] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Radiol, Naples, Italy
[7] AOU Policlin Paolo Giaccone, Dept Oncol, Palermo, Italy
[8] Ist Nazl Tumori IRCCS Fdn G Pascale, Unit Patol, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
212P
引用
收藏
页码：S93 / S93
页数：1
相关论文
共 50 条
  • [1] Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET).
    Morse, Michael
    Halperin, Daniel M.
    Uronis, Hope Elizabeth
    Hsu, David S.
    Hurwitz, Herbert
    Bolch, Emily
    Warren, Dana
    Haley, Sherri
    John, Lisa
    Moyer, Ashley
    Rushing, Christel N.
    Niedzwiecki, Donna
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [2] Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET)
    Morse, Michael A.
    Crosby, Erika J.
    Halperin, Daniel M.
    Uronis, Hope E.
    Hsu, S. David
    Hurwitz, Herbert I.
    Rushing, Christel
    Bolch, Emily K.
    Warren, Dana A.
    Moyer, Ashley N.
    Lowe, Melissa E.
    Niedzwiecki, Donna
    JOURNAL OF NEUROENDOCRINOLOGY, 2025,
  • [3] A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs)
    Halperin, Daniel M.
    Liu, Suyu
    Dasari, Arvind
    Fogelman, David R.
    Bhosale, Priya
    Mahvash, Armeen
    Dervin, Shannon
    Estrella, Jeannelyn
    Cortazar, Patricia
    Maru, Dipen M.
    Mckenna, Edward Francis
    Wistuba, Ignacio Ivan
    Schulze, Katja
    Futreal, Phillip Andrew
    Darbonne, Walter C.
    Yun, Cindy
    Hwu, Patrick
    Yao, James C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [4] A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors.
    Kulke, M. H.
    Stuart, K.
    Earle, C. C.
    Bhargava, P.
    Clark, J. W.
    Enzinger, P. C.
    Meyerhardt, J.
    Attawia, M.
    Lawrence, C.
    Fuchs, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 189S - 189S
  • [5] Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.
    Corti, Francesca
    Amoroso, Vito
    Campana, Davide
    Brizzi, Maria Pia
    Panzuto, Francesco
    Puliafito, Ivana
    Prinzi, Natalie
    Milione, Massimo
    Niger, Monica
    Antista, Maria
    Raimondi, Alessandra
    Morano, Federica
    Prisciandaro, Michele
    Beninato, Teresa
    Pagani, Filippo
    Randon, Giovanni
    Pulice, Iolanda
    Di Bartolomeo, Maria
    De Braud, Filippo G.
    Pusceddu, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] A phase II study of pemetrexed in patients (pts) with advanced neuroendocrine tumors (NETs)
    Bhargava, P.
    Earle, C. C.
    Zhu, A. X.
    Clark, J. W.
    Vincitore, M.
    Battu, S.
    Regan, E.
    Lawrence, C.
    Kulke, M. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Kizilgul, Muhammed
    Delibasi, Tuncay
    TRANSLATIONAL GASTROINTESTINAL CANCER, 2015, 4 (01) : 39 - 56
  • [8] Phase II Study of Sunitinib Following Hepatic Artery Embolization for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Strosberg, Jonathan
    Campos, Tiffany
    Kvols, Larry
    PANCREAS, 2010, 39 (02) : 280 - 281
  • [9] Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
    Kulke, MH
    Stuart, K
    Enzinger, PC
    Ryan, DP
    Clark, JW
    Muzikansky, A
    Vincitore, M
    Michelini, A
    Fuchs, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) : 401 - 406
  • [10] Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study
    Pavel, Marianne
    Lahner, Harald
    Hoersch, Dieter
    Rinke, Anja
    Denecke, Timm
    Koch, Arend
    Regnault, Benjamin
    Helbig, Dorit
    Hoffmanns, Philipp
    Raderer, Markus
    ONCOLOGIST, 2024, : e643 - e654
12345